Identification of host range mutants of myxoma virus with altered oncolytic potential in human glioma cells

Journal of NeuroVirology

Volumn 13, Issue 6, 2007, Pages 549-560

  Barrett, John W ^a   Alston, Lindsay R ^a   Wang, Fuan ^a   Stanford, Marianne M ^a   Gilbert, Philippe Alexandre ^a   Gao, Xiujuan ^a   Jimenez, June ^a   Villeneuve, Danielle ^a   Forsyth, Peter ^b   McFadden, Grant ^a,c  

^a ROBARTS RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

^c UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Glioblastoma; Host range; Poxvirus; Tropism; Virotherapy

Indexed keywords

ONCOLYTIC MYXOMA VIRUS; ONCOLYTIC VIRUS; PROTEIN KINASE B; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; CYTOLYSIS; DRUG CYTOTOXICITY; DRUG SAFETY; ENZYME ACTIVATION; GENE CONSTRUCT; GENE DELETION; GENE EXPRESSION; GENE FUNCTION; GLIOMA CELL; HUMAN; HUMAN CELL; MYXOMA VIRUS; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; VIRUS CELL INTERACTION; VIRUS GENE; VIRUS IDENTIFICATION; VIRUS INFECTION; VIRUS REPLICATION; VIRUS STRAIN; WILD TYPE;

ANIMALS; GLIOMA; HUMANS; MYXOMA VIRUS; ONCOLYTIC VIRUSES; RABBITS; VIRULENCE; VIRUS REPLICATION;

MUS; MYXOMA VIRUS; ORYCTOLAGUS CUNICULUS; POXVIRIDAE;

EID: 37549034204     PISSN: 13550284     EISSN: None     Source Type: Journal    
DOI: 10.1080/13550280701591526     Document Type: Article

References (39)

1. Barrett, J. W., Chang, C Shun, Wang, G., Werden, S. J., Shao, Z., Barrett, C., Gao, X., Belsito, T. A., Villenevue, D. and McFadden, G. (2007) Myxoma virus M063R is a host range gene essential for virus replication in rabbit cells. Virology, 361, pp. 123-132.
2. Barrett, J. W., Sypula, J., Wang, F., Alston, L. R., Shao, Z., Gao, X., Irvine, T. S. and McFadden, G. (2007) M135R is a novel cell surface virulence factor of myxoma virus. J Virol, 81, pp. 106-114.
3. Barry, M., Hnatiuk, S., Mossman, K., Lee, S. F., Boshkov, L. and McFadden, G. (1997) The myxoma virus M-T4 gene encodes a novel RDEL-containing protein that is retained within the endoplasmic reticulum and is important for the productive infection of lymphocytes. Virology, 239, pp. 360-377.
4. Franken, N. A., Rodermond, H. M., Stap, J., Haveman, J. and van Bree, C. (2006) Clonogenic assay of cells in vitro. Nat Protoc, 1, pp. 2315-2319.
5. Gaddy, D. F. and Lyles, D. S. (2007) Oncolytic vesicular stomatitis virus induces apoptosis via signaling through PKR, Fas, and Daxx. J Virol, 81, pp. 2792-2804.
6. Hill, C., Hunter, S. B. and Brat, D. J. (2003) Genetic markers in glioblastoma: Prognostic significance and future therapeutic implications. Adv Anat Pathol, 10, pp. 212-217.
7. Hnatiuk, S., Barry, M., Zeng, W., Liu, L., Lucas, A., Percy, D. and McFadden, G. (1999) Role of the C-terminal RDEL motif of the myxoma virus M-T4 protein in terms of apoptosis regulation and viral pathogenesis. Virology, 263, pp. 290-306.
8. Ishii, N., Maier, D., Merlo, A., Tada, M., Sawamura, Y., Diserens, A. C. and Van Meir, E. G. (1999) Frequent co-alterations of TP53, p16/CDKN2A, p14ARF, PTEN tumor suppressor genes in human glioma cell lines. Brain Pathol, 9, pp. 469-479.
9. Johnston, J. B. and McFadden, G. (2004) Technical knockout: understanding poxvirus pathogenesis by selectively deleting viral immunomodulatory genes. Cell Microbiol, 9, pp. 695-705.
10. King, G. D., Curtin, J. F., Candolfi, M., Kroeger, K., Lowenstein, P. R. and Castro, M. G. (2005) Gene therapy and targeted toxins for glioma. Curr Gene Ther, 5, pp. 535-557.
11. Knobbe, C. B., Trampe-Kieslich, A. and Reifenberger, G. (2005) Genetic alteration and expression of the phosphoinositol-3-kinase/Akt pathway genes PIK3CA and PIKE in human glioblastomas. Neuropathol Appl Neurobiol, 31, pp. 486-490.
12. Li, J., Yen, C., Liaw, D., Podsypanina, K., Bose, S., Wang, S. I., Puc, J., Miliaresis, C., Rodgers, L., McCombie, R., Bigner, S. H., Giovanella, B. C., Ittmann, M., Tycko, B., Hibshoosh, H., Wigler, M. H. and Parsons, R. (1997) PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science, 275, pp. 1943-1947.
13. Liu, T. C., Galanis, E. and Kirn, D. (2007) Clinical trial results with oncolytic virotherapy: A century of promise, a decade of progress. Nat Clin Pract Oncol, 4, pp. 101-117.
14. Liu, T. C. and Kirn, D. (2007) Systemic efficacy with oncolytic virus therapeutics: Clinical proof-of-concept and future directions. Cancer Res, 67, pp. 429-432.
15. Lun, X., Yang, W., Alain, T., Shi, Z-Q, Muzik, H., Barrett, J. W., McFadden, G., Bell, J., Hamilton, M. G., Senger, D. L. and Forsyth, P. A. (2005) Myxoma virus is a novel oncolytic virus with significant antitumor activity against experimental human gliomas. Cancer Res, 65, pp. 9982-9990.
16. Macen, J. L., Graham, K. A., Lee, S. F., Schreiber, M., Boshkov, L. K. and McFadden, G. (1996) Expression of the myxoma virus tumor necrosis factor receptor homologue (T2) and M11L genes is required to prevent virus-induced apoptosis in infected rabbit T lymphocytes. Virology, 218, pp. 232-237.
17. Macen, J. L., Upton, C., Nation, N. and McFadden, G. (1993) SERP1, a serine proteinase inhibitor encoded by myxoma virus, is a secreted glycoprotein that interferes with inflammation. Virology, 195, pp. 348-363.
18. McFadden, G. (2005) Poxvirus Tropism. Nature Reviews Microbiology, 3, pp. 201-213.
19. Mellinghoff, I. K., Wang, M. Y., Vivanco, I., Haas-Kogan, D. A., Zhu, S., Dia, E. Q., Lu, K. V., Yoshimoto, K., Huang, J. H., Chute, D. J., Riggs, B. L., Horvath, S., Liau, L. M., Cavenee, W. K., Rao, P. N., Beroukhim, R., Peck, T. C., Lee, J. C., Sellers, W. R., Stokoe, D., Prados, M., Cloughesy, T. F., Sawyers, C. L. and Mischel, P. S. (2005) Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med, 353, pp. 2012-2024.
20. Merrill, M. K., Selznick, L. A. and Gromeier, M. (2006) Oncolytic viruses fro the treatment of malignant glioma. Expert Opin Ther Patents, 16, pp. 363-371.
21. Mossman, K., Lee, S. F., Barry, M., Boshkov, L. and McFadden, G. (1996) Disruption of M-T5, a novel myxoma virus gene member of poxvirus host range superfamily, results in dramatic attenuation of myxomatosis in infected European rabbits. J Virol, 70, pp. 4394-4410.
22. Nash, P., Barry, M., Seet, B. T., Veugelers, K., Hota, S., Heger, J., Hodgkinson, C., Graham, K., Jackson, R. J. and McFadden, G. (2000) Post-translational modification of the myxoma-virus anti-inflammatory serpin SERP-1 by a virally encoded sialyltransferase. Biochem J, 347, pp. 375-382.
23. Opgenorth, A., Graham, K., Nation, N., Strayer, D. and McFadden, G. (1992) Deletion analysis of two tandemly arranged virulence genes in myxoma virus, M11L and myxoma growth factor. J Virol, 66, pp. 4720-4731.
24. Parato, K. A., Senger, D., Forsyth, P. A. and Bell, J. C. (2005) Recent progress in the battle between oncolytic viruses and tumours. Nat Rev Cancer, 5, pp. 965-976.
25. Rao, R. D. and James, C. D. (2004) Altered molecular pathways in gliomas: An overview of clinically relevant issues. Semin Oncol, 31, pp. 595-604.
26. Roberts, M. S., Lorence, R. M., Groene, W. S. and Bamat, M. K. (2006) Naturally oncolytic viruses. Curr Opin Mol Ther, 8, pp. 314-321.
27. Schreiber, M., Sedger, L. and McFadden, G. (1997) Distinct domains of M-T2, the myxoma virus TNF receptor homolog, mediate extracellular TNF binding and intracellular apoptosis inhibition. J Virol, 71, pp. 2171-2181.
28. Stanford, M. M., Barrett, J. W., Nazarian, S. H., Werden, S. and McFadden, G. (2007) Oncolytic virotherapy synergism with signaling inhibitors: Rapamycin increases myxoma virus tropism for human tumor cells. J Virol, 81, pp. 1251-1260.
29. Steck, P. A., Pershouse, M. A., Jasser, S. A., Yung, W. K., Lin, H., Ligon, A. H., Langford, L. A., Baumgard, M. L., Hattier, T., Davis, T., Frye, C., Hu, R., Swedlund, B., Teng, D. H. and Tavtigian, S. V. (1997) Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet, 15, pp. 356-362.
30. Stojdl, D. F., Lichty, B. D., Oever, B R ten, Paterson, J. M., Power, A. T., Knowles, S., Marius, R., Reynard, J., Poliquin, L., Atkins, H., Brown, E. G., Durbin, R. K., Durbin, J. E., Hiscott, J. and Bell, J. C. (2003) VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer Cell, 4, pp. 263-275.
31. Sypula, J., Wang, F., Ma, Y., Bell, J. and McFadden, G. (2004) Myxoma virus tropism in human tumor cells. Gene Ther Mol Biol, 8, pp. 103-114.
32. Tong, A. (2006) Oncolytic viral therapy for human cancer: Challenges revisited. Drug Dev Res, 66, pp. 260-277.
33. Upton, C., Macen, J. L., Schreiber, M. and McFadden, G. (1991) Myxoma virus expresses a secreted protein with homology to the tumor necrosis factor receptor gene family that contributes to viral virulence. Virology, 184, pp. 370-382.
34. Upton, C., Mossman, K. and McFadden, G. (1992) Encoding of a homolog of the IFN-gamma receptor by myxoma virus. Science, 258, pp. 1369-1372.
35. Wang, G., Barrett, J. W., Stanford, M., Werden, S. J., Johnston, J. B., Gao, X., Sun, M., Cheng, J. Q. and McFadden, G. (2006) Infection of human cancer cells with myxoma virus requires Akt activation via interaction with a viral ankyrin-repeat host range factor. Proc Natl Acad Sci U S A, 103, pp. 4640-4645.
36. Werden, S. J., Barrett, J. W., Wang, G., Stanford, M. M. and McFadden, G. (2007) M-T5, the ankyrin repeat, host range protein of myxoma virus, activates Akt and can be functionally replaced by cellular PIKE-A. J Virol, 81, pp. 2340-2348.
37. Wollmann, G., Robek, M. D. and Pol, A N van den (2007) Variable deficiencies in the interferon response enhance susceptibility to vesicular stomatitis virus oncolytic actions in glioblastoma cells but not in normal human glial cells. J Virol, 81, pp. 1479-1491.
38. Wollmann, G., Tattersall, P. and Pol, A N van den (2005) Targeting human glioblastoma cells: Comparison of nine viruses with oncolytic potential. J Virol, 79, pp. 6005-6022.
39. Woo, Y., Adusumilli, P. S. and Fong, Y. (2006) Advances in oncolytic viral therapy. Curr Opin Investig Drugs, 7, pp. 549-559.